# Prediabetes

Identify prediabetes with fasting glucose, HbA1c, or oral glucose tolerance testing; then stratify progression risk by glycemic burden and prioritize structured weight-loss and activity intervention, adding metformin selectively for patients at highest risk of type 2 diabetes.

**Clinical question:** How should clinicians diagnose, stratify, and intervene in adults with prediabetes to prevent type 2 diabetes?

Updated: 2026-09-16T00:35:41.367209+00:00

## What matters in practice
- For asymptomatic adults aged 35 to 70 years with overweight or obesity, screen with HbA1c, fasting plasma glucose, or a 75-g oral glucose tolerance test and link abnormal results to preventive intervention. [1][21][23]
- Prediabetes is identified by HbA1c 5.7% to 6.4%, fasting plasma glucose 100 to 125 mg/dL, or 2-hour glucose 140 to 199 mg/dL after a 75-g oral glucose tolerance test. [1][15][16][22]
- Do not treat all glycemic phenotypes as equivalent: concurrence of two or three abnormal glycemic criteria denotes greater diabetes risk than one abnormal criterion and supports more intensive prevention. [14]
- A structured lifestyle program targeting approximately 7% weight loss and at least 150 minutes weekly of moderate-intensity activity reduced incident diabetes by 58% in the Diabetes Prevention Program. [17]
- Consider metformin, typically at total doses of at least 1,500 mg/day in trial evidence, for selected high-risk patients when lifestyle intervention alone is insufficient; prevention use remains off-label in the United States. [16][17][18]
- After gestational diabetes, perform a 75-g oral glucose tolerance test 4 to 12 weeks postpartum; women with both prior gestational diabetes and prediabetes have substantial benefit from lifestyle intervention or metformin. [2]

## Whom to screen and which test to order

Use screening to identify patients who can be referred to a proven prevention intervention.

Screen asymptomatic adults aged 35 to 70 years with overweight or obesity for prediabetes and type 2 diabetes. Acceptable screening tests are HbA1c, fasting plasma glucose (FPG), and the 75-g oral glucose tolerance test (OGTT). The result should trigger a documented prevention plan rather than diagnosis alone. [1][21][23]

Order FPG when a fasting specimen is feasible and HbA1c when fasting access is a barrier. Use a 75-g OGTT when post-load dysglycemia is clinically important to resolve, including postpartum testing after gestational diabetes; the test requires overnight fasting followed by a standardized 75-g glucose load and plasma glucose measurement at fasting and 2 hours. [2][5]

A single abnormal screening result establishes a prevention opportunity but does not identify a uniform-risk population. Most patients meet only one glycemic definition; documenting whether abnormalities are present on one, two, or all three tests improves risk discussion and prioritization of intensive intervention. [14]
- HbA1c 5.7% to 6.4% identifies prediabetes; HbA1c values of 6.0% to 6.4% have been recognized as particularly high risk for future diabetes. [1][15][16]
- FPG 100 to 125 mg/dL identifies impaired fasting glucose by ADA criteria. [1][8][22]
- Two-hour plasma glucose 140 to 199 mg/dL after a 75-g OGTT identifies impaired glucose tolerance. [15][16]
- Use plasma glucose-based testing when a diagnostic OGTT is required after gestational diabetes; a 4- to 12-week postpartum OGTT is recommended. [2]

*Glycemic tests used to identify prediabetes and how results change preventive intensity. [1][2][14][15][16][22]*

| Test | Prediabetes range | Clinical use | Action after abnormal result |
| --- | --- | --- | --- |
| HbA1c | 5.7% to 6.4% [1][16] | Convenient nonfasting screening test [21][23] | Refer to a structured lifestyle program; assess whether FPG or OGTT is also abnormal to refine risk. [14][17] |
| Fasting plasma glucose | 100 to 125 mg/dL [1][22] | Fasting screening and impaired fasting glucose classification [1][21] | Document fasting status, initiate prevention intervention, and consider further phenotyping if risk assessment will alter intensity. [14] |
| 75-g OGTT, 2-hour glucose | 140 to 199 mg/dL [15][16] | Detects impaired glucose tolerance; recommended postpartum after gestational diabetes. [2][5] | Treat as a high-priority prevention result, particularly when combined with abnormal HbA1c or FPG. [14] |

## Stratify by glycemic burden and reproductive history

Intensity should follow diabetes risk, not the diagnostic label alone.

Classify glycemic burden by the number of abnormal prediabetes criteria. Patients with one abnormal criterion represent an elevated-risk group, whereas two abnormal criteria identify higher risk and all three identify very high risk for progression; this framework is useful when deciding how urgently to deploy intensive lifestyle treatment, pharmacotherapy, and follow-up. [14]

Impaired fasting glucose and impaired glucose tolerance are not interchangeable phenotypes. FPG detects fasting dysglycemia, while OGTT identifies post-load dysglycemia; a patient with normal FPG may still have impaired glucose tolerance, and a patient with either phenotype warrants a prevention intervention. [5][15][16]

A history of gestational diabetes materially changes preventive priority. In women with both prior gestational diabetes and prediabetes, a post hoc Diabetes Prevention Program analysis found that 12 months of lifestyle intervention or metformin improved glycemic control and reduced type 2 diabetes risk by 50% to 60% versus controls. [2]
- Prioritize high-intensity referral for patients with multiple abnormal glycemic tests rather than assuming risk is identical across HbA1c-, FPG-, and OGTT-defined prediabetes. [14]
- For women with gestational diabetes, schedule the postpartum OGTT before delivery or at discharge and complete testing at 4 to 12 weeks postpartum. [2]
- Address food, housing, and medication insecurity when building a prevention plan for younger adults, who have low testing and prevention-program participation rates and may face disproportionate social barriers. [1]

*Practical risk branches for selecting preventive intensity. [2][14]*

| Risk branch | Discriminator | Next action |
| --- | --- | --- |
| Elevated glycemic risk | One abnormal prediabetes criterion [14] | Refer to a structured diet-and-physical-activity program and reassess glycemia to determine trajectory. [6][17] |
| High glycemic risk | Two abnormal prediabetes criteria [14] | Use intensive lifestyle intervention; discuss metformin when risk remains high despite sustained lifestyle management. [16] |
| Very high glycemic risk | All three abnormal prediabetes criteria [14] | Prioritize rapid program enrollment, address barriers to participation, and consider adjunctive metformin. [14][16][17] |
| Post-gestational diabetes | Prior gestational diabetes plus postpartum prediabetes [2] | Use lifestyle intervention or metformin to reduce subsequent type 2 diabetes risk; optimize broader metabolic risk factors. [2] |

## Prescribe a structured lifestyle intervention rather than general advice

The strongest preventive effect comes from a behavioral program with explicit weight and activity targets.

Refer patients with prediabetes to a structured combined diet, physical-activity, and behavioral program rather than offering unstructured counseling alone. The Diabetes Prevention Program intensive lifestyle intervention targeted approximately 7% loss of initial body weight through a low-calorie, low-fat dietary pattern plus at least 150 minutes weekly of moderate-intensity physical activity and reduced incident diabetes by 58%. [4][17]

Make the prescription measurable: set an initial weight-loss target of approximately 7% of baseline weight, schedule at least 150 minutes per week of moderate-intensity activity, and use goal planning and self-monitoring of dietary intake, activity, and weight. Long-term follow-up data support sustained benefit from intensive lifestyle intervention. [2][4][17]

When access is limited, prioritize referral to an established diabetes prevention lifestyle-change program. National policy recommendations specifically emphasize improving clinician referral, payment coverage, and availability of National Diabetes Prevention Program and Medicare Diabetes Prevention Program services because screening without connection to intervention leaves preventable risk unaddressed. [17]
- Frame the intervention as diabetes prevention, not solely weight management: lifestyle programs reduce progression to diabetes in high-risk adults. [6][10]
- Use combined diet and physical-activity programs; the Community Preventive Services Task Force recommends this model for adults at increased type 2 diabetes risk. [12][20]
- For postpartum patients with gestational diabetes, include metabolic risk-factor optimization alongside lifestyle treatment. [2]

*Elements of an evidence-based lifestyle prescription for prediabetes. [2][4][17]*

| Component | Operational prescription | Outcome basis |
| --- | --- | --- |
| Weight target | Lose approximately 7% of initial body weight. [4][17] | Part of the Diabetes Prevention Program intervention associated with 58% lower diabetes incidence. [17] |
| Physical activity | Perform at least 150 minutes weekly of moderate-intensity activity. [2][4] | Part of the Diabetes Prevention Program lifestyle strategy. [4][17] |
| Dietary strategy | Use a calorie-reduced, low-fat eating pattern with individualized behavioral support. [2][4] | Dietary modification combined with activity and behavior change prevents progression to diabetes. [6][10] |
| Behavioral delivery | Use goal planning and self-monitoring rather than one-time advice. [2] | These components were included in intensive interventions with long-term benefit. [2][17] |

## When to add metformin for diabetes prevention

Use metformin selectively as an adjunct to—not a substitute for—structured lifestyle intervention.

Consider metformin for patients with prediabetes who remain at high risk after 3 to 6 months of intensive lifestyle management, particularly patients who are younger, have overweight or obesity, have worsening glycemia, or have high cardiovascular risk. This is a selective prevention strategy rather than routine drug treatment for every patient with one mildly abnormal glycemic result. [16]

Clinical trial and synthesis data describe preventive efficacy with metformin doses usually totaling at least 1,500 mg/day. In the Diabetes Prevention Program, metformin reduced diabetes incidence by 31% versus placebo over a mean 2.8 years, compared with a larger effect from intensive lifestyle intervention; the reduction persisted at 10 years, with an 18% lower diabetes incidence reported in follow-up. [4][18]

Use metformin as off-label prevention therapy in the United States; federal recommendations have called for FDA review and approval for diabetes prevention, underscoring that this is not an FDA-approved prevention indication. Check estimated glomerular filtration rate before prescribing and monitor renal function; published review data support use down to eGFR 30 mL/min/1.73 m² with appropriate caution and dose/renal monitoring. [16][17]
- Favor lifestyle intervention over metformin when the patient can engage in the full program, because the Diabetes Prevention Program lifestyle arm produced a greater reduction in incident diabetes than metformin. [4][17][18]
- Discuss metformin early for prior gestational diabetes with prediabetes, where both metformin and lifestyle intervention reduced diabetes risk by 50% to 60% versus controls in a post hoc analysis. [2]
- Do not present metformin as a replacement for activity, dietary change, or weight-loss goals; available prevention studies evaluated it alongside lifestyle-focused management. [16][18]

*Choosing lifestyle treatment alone versus adding metformin. [2][4][16][17][18]*

| Clinical situation | Preferred approach | Rationale |
| --- | --- | --- |
| Prediabetes with one abnormal criterion and ability to participate in program | Structured lifestyle intervention first. [17] | The Diabetes Prevention Program lifestyle strategy reduced diabetes incidence by 58%. [17] |
| Persistent high-risk prediabetes after 3 to 6 months of intensive lifestyle management | Consider adjunctive metformin, with trial evidence usually using at least 1,500 mg/day. [16] | Metformin can reduce or delay type 2 diabetes progression, although effect size was smaller than intensive lifestyle intervention in DPP. [4][18] |
| Prior gestational diabetes plus prediabetes | Use intensive lifestyle intervention or metformin; individualize based on feasibility and glycemic risk. [2] | Both interventions reduced type 2 diabetes risk by 50% to 60% versus controls in post hoc DPP analysis. [2] |
| eGFR below 30 mL/min/1.73 m² | Do not initiate metformin without specialist-level reassessment of alternatives and renal risk. | Published review evidence supports metformin only down to eGFR 30 mL/min/1.73 m² with caution and renal monitoring. [16] |

## Monitor glycemia, program engagement, and progression risk

Follow-up should determine whether prevention is working and whether the patient has crossed into diabetes.

At follow-up, repeat the glycemic modality that identified the abnormality when possible, reassess weight and weekly activity against the approximately 7% and 150-minute targets, and determine whether the patient enrolled in and is attending a structured program. Failure to enroll is a treatment failure of access or implementation, not simply a patient preference issue. [2][4][17]

Escalate prevention intensity when glycemia worsens, when a second or third prediabetes criterion becomes abnormal, or when lifestyle targets are not being met despite structured support. Multiple abnormal glycemic criteria identify progressively higher diabetes risk and provide a practical trigger to revisit metformin, social barriers, and program delivery. [14][16]

Postpartum follow-up requires particular rigor: complete the 4- to 12-week OGTT after gestational diabetes, identify prediabetes or diabetes promptly, and continue metabolic risk-factor optimization because prior gestational diabetes confers a high-risk prevention phenotype. [2]
- Track weight change from baseline rather than relying on self-reported dietary adherence alone; the evidence-based program target is approximately 7% initial weight loss. [4][17]
- Track documented weekly moderate-intensity activity against the at-least-150-minutes-per-week target. [2][4]
- Reassess pharmacologic prevention if high-risk patients have worsening glycemia despite 3 to 6 months of intensive lifestyle management. [16]

*Follow-up triggers that should change the prevention plan. [2][14][16]*

| Finding at reassessment | Interpretation | Next step |
| --- | --- | --- |
| No enrollment in structured lifestyle program | The evidence-based first-line intervention has not been delivered. [17] | Identify referral, coverage, transportation, scheduling, food-access, or postpartum barriers and connect to an available lifestyle-change program. [1][17] |
| No progress toward 7% weight-loss or 150-minute activity targets | Lifestyle dose is below the Diabetes Prevention Program target. [2][4] | Intensify behavioral support, self-monitoring, and goal planning. [2] |
| Additional glycemic criterion becomes abnormal | Risk category rises from elevated to high or very high risk. [14] | Increase prevention intensity and discuss adjunctive metformin when appropriate. [14][16] |
| History of gestational diabetes without completed postpartum OGTT | A recommended high-risk screening step is incomplete. [2] | Arrange a 75-g OGTT as soon as feasible after the recommended 4- to 12-week postpartum interval. [2] |

## References
1. New USPSTF Recommendations for Screening for Prediabetes and Type 2 Diabetes: An Opportunity to Create — jamanetwork.com — https://jamanetwork.com/journals/jama/fullarticle/2783444
2. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention ... - JACC — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2026.03.056
3. Optimal exercise dose for glycemic control in prediabetes across ... — www.cell.com — https://www.cell.com/iscience/fulltext/S2589-0042(25)02241-2
4. Primary Prevention of Cardiovascular Disease in Diabetes Mellitus — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2017.07.001
5. Glucose Tolerance Testing and Diabetes Risk Assessment | Endocrinology | Clinical Sciences | Health sciences | Topics | Nature Index — www.nature.com — https://www.nature.com/nature-index/topics/l4/glucose-tolerance-testing-and-diabetes-risk-assessment
6. Lifestyle Interventions for Patients With and at Risk for Type 2 Diabetes: A Systematic Review and Meta-analysis: Annals of Internal Medicine: Vol 159, No 8 — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/0003-4819-159-8-201310150-00007
7. “Preventing the Progression: The Power of Lifestyle Interventions in Prediabetic Individuals—A Systematic Review” - Bhardwaj - Clinical Endocrinology - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/cen.70077?af=R
8. Prediabetes and the risk of atrial fibrillation: systematic review, meta ... — academic.oup.com — https://academic.oup.com/eurjpc/advance-article/doi/10.1093/eurjpc/zwag215/8654926
9. Lower-Intensity Interventions for Prediabetes: A Systematic Review - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0749379723002362
10. Long-term lifestyle intervention can reduce the development of type 2 diabetes mellitus in subjects with prediabetes: A systematic review and meta-analysis - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S016882272400127X
11. Predisease: When Does it Make Sense? - Oxford Academic — academic.oup.com — https://academic.oup.com/epirev/article/33/1/122/487319
12. Value of Lifestyle Intervention to Prevent Diabetes and Sequelae - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0749379714005807
13. A call to action on prediabetes : JAAPA — journals.lww.com — https://journals.lww.com/jaapa/fulltext/2018/10000/a_call_to_action_on_prediabetes.5.aspx?Ppt=Article%7Cjaapa%3A2018%3A10000%3A00005%7C10.1097%2F01.jaa.0000545064.33107.8f%7C
14. Reframing prediabetes: A call for better risk stratification and intervention - Kim - 2024 - Journal of Internal Medicine - Wiley Online Library — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/joim.13786
15. Associations of HbA1c and fasting plasma glucose with incident diabetes: Implications for pre-diabetes thresholds in a Japanese population - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1751991816300584
16. Metformin: Therapeutic profile in the treatment of type 2 diabetes — dom-pubs.onlinelibrary.wiley.com — https://dom-pubs.onlinelibrary.wiley.com/doi/full/10.1111%2Fdom.15663
17. The National Clinical Care Commission Report to Congress: Leveraging Federal Policies and Programs to Prevent Diabetes in People With Prediabetes | Diabetes Care | American Diabetes Association — diabetesjournals.org — https://diabetesjournals.org/care/article/46/2/e39/148317/The-National-Clinical-Care-Commission-Report-to
18. The Effectiveness of Metformin in Diabetes Prevention: A Systematic Review and Meta-Analysis - PMC — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611985?term=%22Cureus%22%5Bjour%5D
19. Metformin for people with impaired glucose tolerance or impaired fasting blood glucose - Lü, Q - 2010 | Cochrane Library — www.cochranelibrary.com — https://www.cochranelibrary.com/es/cdsr/doi/10.1002/14651858.CD008558//es
20. Value of lifestyle intervention to prevent diabetes and sequelae - PubMed — www.ncbi.nlm.nih.gov — http://www.ncbi.nlm.nih.gov/pubmed/25498548
21. [PDF] preventing chronic disease - CDC — www.cdc.gov — https://www.cdc.gov/pcd/issues/2023/pdf/23_0173.pdf
22. Management of Newly Diagnosed Type 2 Diabetes Mellitus (T2DM ... — publications.aap.org — https://publications.aap.org/pediatrics/article/131/2/364/31847/Management-of-Newly-Diagnosed-Type-2-Diabetes
23. Prevalence of Testing for Diabetes Among US Adults With Overweight or Obesity, 2016–2019 — www.cdc.gov — https://www.cdc.gov/pcd/issues/2023/23_0173.htm
24. Time to Glucose Peak During an Oral Glucose Tolerance Test Identifies Prediabetes Risk - PMC — www.ncbi.nlm.nih.gov — http://www.ncbi.nlm.nih.gov/pmc/articles/5658251

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.